Neglected tropical diseases and infectious illnesses: potential targeted peptides employed as hits compounds in drug design

J Drug Target. 2021 Mar;29(3):269-283. doi: 10.1080/1061186X.2020.1837843. Epub 2020 Oct 27.

Abstract

Neglected Tropical Diseases (NTDs) and infectious illnesses, such as malaria, tuberculosis and Zika fever, represent a major public health concern in many countries and regions worldwide, especially in developing ones. They cause thousands of deaths per year, and certainly compromise the life of affected patients. The drugs available for therapy are toxic, have considerable adverse effects, and are obsolete, especially with respect to resistance. In this context, targeted peptides are considered promising in the design of new drugs, since they have specific action and reduced toxicity. Indeed, there is a rising interest in these targeted compounds within the pharmaceutical industry, proving their importance to the Pharmaceutical Sciences field. Many have been approved by the Food and Drug Administration (FDA) to be used as medicines, plus there are more than 300 peptides currently in clinical trials. The main purpose of this review is to show the most promising potential targeted peptides acting as hits molecules in NTDs and other infectious illnesses. We hope to contribute to the discovery of medicines in this relatively neglected area, which will be extremely useful in improving the health of many suffering people.

Keywords: Viruses; bacteria; peptide-based drug design; potential treatments; protozoa.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Communicable Diseases / drug therapy*
  • Communicable Diseases / microbiology
  • Drug Design
  • Humans
  • Molecular Targeted Therapy
  • Neglected Diseases / drug therapy*
  • Neglected Diseases / physiopathology
  • Peptides / administration & dosage*
  • Peptides / adverse effects
  • Peptides / pharmacology
  • Public Health
  • Tropical Medicine

Substances

  • Peptides